Comparing two myeloma treatments for new patients
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug combination (HLX15-SC) against an approved treatment (DARZALEX FASPRO) along with lenalidomide and dexamethasone for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 years or older
- Newly diagnosed with multiple myeloma and not eligible for a stem cell transplant
- Good overall health (ECOG score 0 or 1)
- Adequate blood counts and kidney/liver function
- Willing to use effective birth control
- No prior cancer treatment for myeloma except a short course of steroids
- No serious heart, lung, or other medical conditions
- No active hepatitis B, C, or HIV infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment combination for multiple myeloma that has returned or stopped responding to previous therapy and has spread outside the bone marrow. It aims to see if the combination can shrink these tumors and improve outcomes.
This trial tests a new combination of three drugs (F182112, isatuximab, and lenalidomide) for people who have just been diagnosed with multiple myeloma and have had little or no prior treatment. The goal is to see if this combination is safe and effective in controlling the disease.
This study compares a new drug (HLX15-IV) with a standard treatment (Darzalex) when both are combined with lenalidomide and dexamethasone, for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see which combination works better and is safe.
This trial tests two different drug combinations for people newly diagnosed with multiple myeloma who are not getting a stem cell transplant right away. It compares one drug (elranatamab) to another (daratumumab), both given with a standard three-drug regimen called RVd Lite, to see which works better.
This trial compares two different combinations of medications for people with newly diagnosed multiple myeloma who are not planning to have a stem cell transplant. It looks at whether adding a targeted antibody drug is as effective as the standard approach.
This trial tests a new combination of two drugs (etentamig and daratumumab) against the current standard of daratumumab plus lenalidomide and dexamethasone in people recently diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see which combination better controls the disease while keeping side effects manageable.
Hear when a new Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.